Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection

A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection

NCT02081079•Gilead Sciences

View on ClinicalTrials.gov

Summary

This study is to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with chronic genotype 4 or 5 hepatitis C virus (HCV) infection as measured by the proportion of subjects with sustained virologic response (SVR12), defined as HCV RNA \< lower limit of quantification (LLOQ) 12 weeks after discontinuation of therapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•HCV RNA ≥ 10\^4 IU/mL at screening
•Chronic genotype 4 or 5 HCV Infection
•Individuals may be treatment naive or treatment experienced
•Presence or absence of cirrhosis, a liver biopsy may be required
•Healthy according to medical history and physical examination with the exception of HCV diagnosis
•Agree to use two forms of highly effective contraception for the duration of the study

Exclusion Criteria

•History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the individual's participation for the full duration of the study or not be in the best interest of the individual in the opinion of the investigator
•Prior exposure to approved or experimental HCV specific direct acting antiviral(s) (DAA) other than NS3/4A protease inhibitors
•History of any other clinically significant chronic liver disease
•Evidence of or history of decompensated liver disease
•HIV or chronic hepatitis B (HBV) infection
•Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)
•Chronic use of immunosuppressive agents or immunomodulatory agents

Locations (5)

Clermont-Ferrand, France

Clichy, France

Limoges, France

Toulouse, France

Villejuif, France

Key Dates

Start Date

March 1, 2014

Primary Completion Date

November 1, 2014

Completion Date

February 1, 2015

Last Updated

November 19, 2018

Enrollment

ACTUAL participants

Conditions

Chronic Genotype 4 HCVChronic Genotype 5 HCV

Interventions

LDV/SOF

DRUG